The upgrade of Passage Bio to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

Equities research analysts at Wedbush lifted their Q1 2025 earnings per share (EPS) estimates for shares of Passage Bio in a ...

Equities researchers at Wedbush issued their FY2029 EPS estimates for Passage Bio in a research note issued to investors on ...

PASG stock opened at $0.47 on Tuesday. Passage Bio has a 52-week low of $0.38 and a 52-week high of $1.79. The firm has a market cap of $29.04 million, a P/E ratio of -0.40 and a beta of 1.55. The ...

Passage Bio, Inc. (NASDAQ: PASG) announced its 2024 financial results, highlighting progress in its PBFT02 gene therapy ...

Upstream Bio completed Phase 2 trial enrollment for verekitug and raised $293 million in an IPO, funding operations ... Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...